Minimal Change Disease Clinical Trials

11 recruitingLast updated: May 21, 2026

There are 11 actively recruiting minimal change disease clinical trials across 15 countries. Studies span Not Applicable, Phase 2, Phase 3. Top locations include Ann Arbor, Michigan, United States, Philadelphia, Pennsylvania, United States, New Hyde Park, New York, United States. Updated daily from ClinicalTrials.gov.


Minimal Change Disease Trials at a Glance

11 actively recruiting trials for minimal change disease are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Ann Arbor, Philadelphia, and New Hyde Park. Lead sponsors running minimal change disease studies include University of Michigan, Northwell Health, and Prof. Dr. Paul Brinkkoetter.

Browse minimal change disease trials by phase

About Minimal Change Disease Clinical Trials

Looking for clinical trials for Minimal Change Disease? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Minimal Change Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Minimal Change Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Alport SyndromeFocal Segmental GlomerulosclerosisImmunoglobulin A Nephropathy+2 more
Travere Therapeutics, Inc.67 enrolled47 locationsNCT05003986
Recruiting
Not Applicable

NEPTUNE Match Study

Nephrotic Syndrome in ChildrenAlport SyndromeFocal Segmental Glomerulosclerosis+6 more
University of Michigan375 enrolled16 locationsNCT04571658
Recruiting

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

Focal Segmental GlomerulosclerosisMinimal Change DiseaseFSGS+1 more
University of Michigan300 enrolled1 locationNCT05650619
Recruiting
Not Applicable

A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)

Nephrotic Syndrome in ChildrenFocal Segmental GlomerulosclerosisMinimal Change Disease
Northwell Health10 enrolled2 locationsNCT05583942
Recruiting
Not Applicable

taVNS for FRNS in Children

Nephrotic Syndrome in ChildrenFocal Segmental GlomerulosclerosisMinimal Change Disease
Northwell Health30 enrolled2 locationsNCT05588063
Recruiting
Phase 2Phase 3

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS)Minimal Change Disease (MCD)
Bio-Thera Solutions192 enrolled1 locationNCT07499700
Recruiting
Phase 2

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135
Recruiting

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

EdemaNephrotic Syndrome in ChildrenMembranous Nephropathy+10 more
University of Michigan150 enrolled1 locationNCT05505500
Recruiting

The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)

Minimal Change DiseaseGlomerulosclerosis, Focal SegmentalIdiopathic Nephrotic Syndrome
Prof. Dr. Paul Brinkkoetter500 enrolled12 locationsNCT03949972
Recruiting

Nephrotic Syndrome Study Network

Membranous NephropathyGlomerulosclerosis, Focal SegmentalMinimal Change Disease (MCD)
University of Michigan1,200 enrolled44 locationsNCT01209000
Recruiting

KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis

Focal Segmental GlomerulosclerosisIgA NephropathyMembranous Nephropathy+4 more
Seoul National University Hospital3,000 enrolled6 locationsNCT03929887